Union Information and Broadcasting Minister Prakash Javadekar said during a press briefing that such claims on
"The
Multiple reports had said that over 130 countries across the globe currently accept Serum Institute of
The latest WHO guidance document shows that
However, a peer-review publication Clinical Infectious Diseases has noted that Covaxin demonstrates protection against the new Covid-19 variants.
The study found that vaccination with Covaxin produced neutralising titres against all key emerging variants tested including B1617 and B117, first identified in India and the UK, respectively.
A modest reduction in neutralisation by a factor of 1.95 was observed against the B1617 variant compared to the vaccine variant.
Top officials in the country said this week that they will begin clinical trials to test the Covaxin vaccine's efficacy in children between two to 18 years of age in 10-12 days.
"Covaxin has been approved by the Drugs Controller General of India for Phase 2 and 3 clinical trials in the age group of two to 18 years. I have been told that trials will begin in the next 10-12 days," V.K. Paul, NITI Aayog's Member Health, had said.
SEE ALSO
Esper, an Android-based development platform, raises $30 million as pandemic accelerates adoption of intelligent devices
The number of working women in India has been steadily declining, here’s why
Indian government threatens legal action against WhatsApp’s new privacy policy – WhatsApp refuses to back down